Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 35, 2013, Pages 14384-14389

  Nold, Marcel F ^a   Mangan, Niamh E ^b   Rudloff, Ina ^a   Cho, Steven X ^a   Shariatian, Nikeh ^a   Samarasinghe, Thilini D ^a   Skuza, Elizabeth M ^a   Pedersen, John ^c   Veldman, Alex ^a   Berger, Philip J ^a   Nold Petry, Claudia A ^a  

^a Ritchie Centre   (United States)

^b MONASH UNIVERSITY   (Australia)

^c Tissupath Pty Ltd   (Australia)

Author keywords

Anti inflammatory therapy; Cytokines; Neonatal immunity; Receptor blockade

Indexed keywords

CD11B ANTIGEN; COLONY STIMULATING FACTOR 1; COMPLEMENT COMPONENT C5A; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 5; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; HISTOPATHOLOGY; HYPEROXIA; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG ALVEOLUS CELL; LUNG DYSPLASIA; LUNG GAS EXCHANGE; LUNG PARENCHYMA; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NEWBORN; NONHUMAN; PERINATAL MORBIDITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANTI-INFLAMMATORY THERAPY; CYTOKINES; NEONATAL IMMUNITY; RECEPTOR BLOCKADE;

ANIMALS; BRONCHOPULMONARY DYSPLASIA; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPEROXIA; INFANT, NEWBORN; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED C57BL; PREGNANCY;

EID: 84883399462     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1306859110     Document Type: Article

References (40)

1. Baraldi E, Carraro S, Filippone M (2009) Bronchopulmonary dysplasia: Definitions and long-term respiratory outcome. Early Hum Dev 85(10, Suppl):S1-S3.
2. Short EJ, et al. (2007) Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: Analysis using a severity-based classification system. Arch Pediatr Adolesc Med 161(11):1082-1087.
3. Short EJ, et al. (2003) Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 112(5):e359.
4. Walter EC, Ehlenbach WJ, Hotchkin DL, Chien JW, Koepsell TD (2009) Low birth weight and respiratory disease in adulthood: A population-based case-control study. Am J Respir Crit Care Med 180(2):176-180.
5. Jobe AJ (1999) The new BPD: An arrest of lung development. Pediatr Res 46(6):641-643.
6. Bose CL, Dammann CE, Laughon MM (2008) BPD and inflammatory biomarkers in the premature neonate. Arch Dis Child Fetal Neonatal Ed 93(6):F455-F461.
7. Ambalavanan N, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (2009) Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 123(4):1132-1141.
8. Bry K, Whitsett JA, Lappalainen U (2007) IL-1beta disrupts postnatal lung morphogenesis in the mouse. Am J Respir Cell Mol Biol 36(1):32-42.
9. Cayabyab RG, et al. (2003) Interleukin-1beta in the bronchoalveolar lavage fluid of premature neonates: A marker for maternal chorioamnionitis and predictor of adverse neonatal outcome. J Matern Fetal Neonatal Med 14(3):205-211.
10. Jónsson B, Tullus K, Brauner A, Lu Y, Noack G (1997) Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 77(3):F198-F201.
11. Rindfleisch MS, Hasday JD, Taciak V, Broderick K, Viscardi RM (1996) Potential role of IL-1 in the development of BPD. J Interferon Cytokine Res 16(5):365-373.
12. Halliday H, Ehrenkranz R, Doyle L (2009) Early (< 8d) postnatal corticosteroids for preventing BPD in preterm infants. Cochrane Database Syst Rev (1):CD001146.
13. Mulrooney N, Jobe AH, Ikegami M (2004) Lung inflammatory responses to intratracheal interleukin-1alpha in ventilated preterm lambs. Pediatr Res 55(4):682-687.
14. Warner BB, Stuart LA, Papes RA, Wispé JR (1998) Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol 275(1 Pt 1):L110-L117.
15. Kallapur SG, et al. (2009) IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolysaccharide. Am J Respir Crit Care Med 179(10):955-961.
16. Cakmak BC, et al. (2012) Association between bronchopulmonary dysplasia and MBL2 and IL1-RN polymorphisms. Pediatr Int 54(6):863-868.
17. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633-652.
18. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720-3732.
19. Rigante D, Leone A, Marrocco R, Laino ME, Stabile A (2011) Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). Rheumatol Int 31(12):1661-1664.
20. Sibley CH, et al. (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes. Arthritis Rheum 64(7):2375-2386.
21. Choi CW, et al. (2009) BPD in a rat model induced by intra-amniotic inflammation and postnatal hyperoxia: Morphometric aspects. Pediatr Res 65(3):323-327.
22. Velten M, Heyob KM, Rogers LK, Welty SE (2010) Deficits in lung alveolarization and function after systemic maternal inflammation and neonatal hyperoxia exposure. J Appl Physiol 108(5):1347-1356.
23. Walsh MC, et al. (2006) Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117(3 Pt 2):S52-S56.
24. Jobe AH (2011) The new bronchopulmonary dysplasia. Curr Opin Pediatr 23(2):167-172.
25. Been JV, et al. (2009) Histologic chorioamnionitis, fetal involvement, and antenatal steroids: Effects on neonatal outcome in preterminfants. Am J Obstet Gynecol 201(6):e1-e8.
26. Clement A, Chadelat K, Sardet A, Grimfeld A, Tournier G (1988) Alveolar macrophage status in BPD. Pediatr Res 23(5):470-473.
27. He S, et al. (2008) MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood. J Leukoc Biol 84(6):1549-1556.
28. Miller JD, Benjamin JT, Kelly DR, Frank DB, Prince LS (2010) Chorioamnionitis stimulates angiogenesis in saccular stage fetal lungs via CC chemokines. Am J Physiol Lung Cell Mol Physiol 298(5):L637-L645.
29. Deng H, Mason SN, Auten RL, Jr. (2000) Lung inflammation in hyperoxia can be prevented by antichemokine treatment in newborn rats. Am J Respir Crit Care Med 162(6):2316-2323.
30. Klesney-Tait J, et al. (2013) Transepithelial migration of neutrophils into the lung requires TREM-1. J Clin Invest 123(1):138-149.
31. de Visser YP, et al. (2009) Sildenafil attenuates pulmonary inflammation, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10:30.
32. Zhang X, et al. (2012) Role of bone marrow-derived mesenchymal stem cells in the prevention of hyperoxia-induced lung injury in newbornmice. Cell Biol Int 36(6):589-594.
33. Alapati D, et al. (2011) Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. Am J Respir Cell Mol Biol 45(6):1169-1177.
34. Nakanishi H, Sugiura T, Streisand JB, Lonning SM, Roberts JD, Jr. (2007) TGF-betaneutralizing antibodies improve pulmonary alveologenesis and vasculogenesis in the injured newborn lung. Am J Physiol Lung Cell Mol Physiol 293(1):L151-L161.
35. Park JW, et al. (2004) Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone. Am J Respir Cell Mol Biol 30(6):830-836.
36. Thebaud B, et al. (2005) VEGF gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: Evidence that angiogenesis participates in alveolarization. Circulation 112(16):2477-2486.
37. Hillman NH, et al. (2010) Inhibitors of inflammation and endogenous surfactant pool size as modulators of lung injury with initiation of ventilation in preterm sheep. Respir Res 11:151.
38. Alejandre-Alcazar MA, et al. (2007) Hyperoxia modulates TGF-beta/BMP signaling in a mouse model of BPD. Am J Physiol Lung Cell Mol Physiol 292(2):L537-L549.
39. Petry C, Fritz G, Pfeilschifter J, Huwiler A (2004) Inhibition of Rho modulates cytokineinduced PGE2 formation in mesangial cells. Biochim Biophys Acta 1636(2-3):108-118.
40. Nold MF, et al. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11(11):1014-1022.